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The External Quality Assurance Program Oversight Labora-
tory (EQAPOL) is a contract awarded by the National Institutes
of Health/National Institute of Allergy and Infectious Diseases/
Division of AIDS (NIH/NIAID/DAIDS) to support the devel-
opment of external proficiency testing programs for flow
cytometry-, ELISpot-, and Luminex bead-based assays (cyto-
kine analytes). The EQAPOL Program is comprised of a Central
Management Team, Central Quality Assurance Unit (CQAU),
Statistical Group, Data Management Group, Biorepository,
Central Laboratory, A3R5 Neutralizing Antibody Assay Valida-
tion Program, and three EQAPOL Oversight Laboratories (EOLs)
described in detail in this issue of Journal of Immunological
Methods (see Ferrari et al. for ELISpot; Staats et al. for ICS by
Flow Cytometry; Sempowski et al. for cytokine-based Luminex).
In addition to proficiency testing, EQAPOL is also tasked with
creating a diverse panel of high-titer (approximately 109 copies/
mL), HIV-1 viral culture supernatants grown in PBMC from seed
stocks (i.e., from plasma samples and other source material)
using a Viral Diversity Core (see Sanchez et al. in this issue) and
in validating immunogenicity assays (see Sarzotti-Kelsoe et al. in
this issue).
The EQAPOL Laboratory Teams (EQAPOL Viral Diversity
Core, Biorepository, Central Laboratory, A3R5 Neutralizing
Antibody Assay Validation Program, and each of the EOLs) are
required to operate under Good Clinical Laboratory Practices
(GCLP), since this is a set of standards designed to facilitate
uniform and consistent data generation and reporting. GCLP
encompasses both quality assurance (QA) and quality control
(QC) principles into its standards. QA proactively and period-
ically reviews the various components of the research process
to assess adherence to standard operating procedures (SOPs)
and policies and to determine the accuracy of research records.
QCmeasures are continuous and carried out on all records (QC
logs,worksheets, etc.) by the Laboratory Teams.While external
laboratories, participating in the EQAPOL proficiency testing
programs, are not required to operate under GCLP, many of
these laboratories are already GCLP-compliant and perform
clinical trial related work. It is for this reason that the program
operates in GCLP compliance as it ensures the quality, integrity,
and validity of the test data.
GCLP was initially designed by the British Association of
Research Quality Assurance (BARQA) in 2003 and later
expanded upon by the NIH/NIAID/DAIDS in 2008 to provide a
regulatory framework to laboratories performing endpoint
assays for HIV-1 human clinical trials (Stiles et al., 2003; Ezzelle
et al., 2008). The two sets of GCLP guidelines were harmonized
in 2009 in order to provide a single set of recommendations
for laboratories to utilize (Sarzotti-Kelsoe et al., 2009). The
process of converting laboratories into GCLP-compliantentities includes initial laboratory assessments and GCLP
training; establishment of SOPs, Quality Management Sys-
tems and Study Plans; quality controlled equipment and
reagents; optimization and validation of applicable assays;
and laboratory audits and corrective action programs. The
EQAPOL CQAU, which has over 10 years of experience in
performing audits, document control and study monitoring
in GCLP compliance, was tasked with implementing these
standards for EQAPOL (Sarzotti-Kelsoe et al., 2009; Ozaki et
al., 2012; Todd et al., 2012).
External Quality Assurance (EQA) Programs serve three
purposes according to GCLP guidance: 1) provide a way for
laboratories to ensure that data generated are timely, accurate,
and clinically appropriate; 2) provide sponsors with assurance
that data generated are of the highest quality; and 3) ensure
that human specimens from clinical trials will be tested
accurately and reliably (Ezzelle et al., 2008). Although GCLP is
a robust set of guidelines governing the conduct of endpoint
assays for clinical trials, there are no specific statements
regarding the management of external proficiency testing
programs. The International Organization for Standardization
(ISO) and International Electrotechnical Commission (IEC) have
created a set of guidelines/requirements (ISO/IEC 17043) for
external proficiency testing programs to follow, so as to provide
extra assurance to participants that the program is operated
competently (ISO/IEC, 2010). ISO/IEC 17043 requirements
primarily apply to management, planning and design, person-
nel, quality assurance, and confidentiality (ISO/IEC, 2010). The
EQAPOL CQAU implemented GCLP, along with many aspects of
ISO/IEC 17043, in an effort to make the program compliant to
the most appropriate quality standards.
In addition to the proficiency testing programs, EQAPOL was
also charged with establishing and characterizing clade-specific
HIV-1 viral culture panels representing world-wide genetic
diversity. These HIV-1 viral diversity panels are created from
HIV-1 positive plasma specimens received from collaborators or
from currently existing viral culture supernatants.
Finally, as an option exercised by the NIAID contract, EQAPOL
was also charged with performing formal validation of specific
immunogenicity assays to be employed as endpoint assays for
HIV vaccine clinical trials. The Neutralizing Antibody Assay for
HIV-1 in A3R5 cells was optimized and formally validated
(Sarzotti-Kelsoe, et al. in this issue) under the oversight of the
EQAPOL CQAU.
This report describes the process by which GCLP compli-
ance was established for the entire EQAPOL Program.
2. Laboratory assessments
Prior to implementing GCLP throughout the EQAPOL
Program, the CQAU performed an overall assessment of
Assist  EQAPOL Laboratory Team  at 
optimizing/validating assay 
(when applicable)
Audit EQAPOL Laboratory Team for GCLP Compliance.
Monitor all Aspects of Kit Assembly, Labeling, Storage, 
Distribution
Assist EQAPOL Laboratory Team in the Establishment 
of Standard Operating Procedures, Document Control, 
Quality Management Systems and Preparing Study 
Plans
Initial EQAPOL Laboratory Team Assessment for GCLP 
Compliance and GCLP Training
Assist EQAPOL Laboratory Team with Corrective 
Actions
Provide audit reports to EQAPOL Laboratory Team and
to Management
Fig. 1. EQAPOL QAU approach to GCLP-compliance for EQAPOL Laboratory
Teams. This schematic diagram illustrates the plan taken by the EQAPOL
CQAU to assess the EQAPOL Laboratory Teams and bring them to
GCLP-compliance.
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taken by the EQAPOL CQAU to bring each EQAPOL Laboratory
Team into GCLP compliance. The laboratory assessment process
did not apply to the A3R5 Validation Program as it was already
operating under GCLP-compliance. The CQAU began the assess-
ment process with an analysis of the organizational structure of
the laboratory, provided documentation of critical areas that
needed to be addressed in order to achieve GCLP compliance,
created a general plan of action, and conducted GCLP training for
all staff members of the laboratory. This introductory training to
the GCLP guidelines discussed the requirements for organization
and personnel training, equipmentmaintenance and calibration,
reagent and specimen maintenance, document control, assay
optimization and validation, and corrective action plans. Each
EQAPOL Laboratory Team started the program with different
levels of adherence to the principles of GCLP, thus laboratory-
specific strategies were developed by the CQAU to address and
close gaps in compliance based on previous experience from
implementing GCLP in domestic and international laboratories
(Ozaki et al., 2012; Gilmour et al., 2007). Successful establish-
ment of GCLP compliance for the Laboratory Teams ranged from
a minimum of three months for those with more quality
experience to approximately two years.
3. Quality Management Systems
In order to effectively implement document and version
control of SOPs, and manage training, equipment andcalibration/maintenance records, the CQAU adopted a Quality
Management System (QMS) (Q-Pulse, Gael Limited, Scotland)
that allowed all of the aforementioned information to be
captured and maintained electronically. The software package
allows laboratory personnel to access SOPs on any computer
with internal server access, which eliminates the need to have
paper copies of SOPs present in the laboratories — further
mitigating the risk of expired/uncontrolled procedures being
used in the laboratory. The use of electronic copies also allows
for better version control as paper copies may be altered while
in use in the laboratory. In addition, the QMS allows the CQAU
to electronically distribute SOPs to laboratory staff, maintain
version control of documents, and manage SOP revision and
training records.
The QMS has also been instrumental in streamlining the
audit process by allowing auditors to complete a report and
present findings electronically to each EQAPOL Program
Team. The use of tablet computers running QMS-specific
applications allows audits to be conducted in a more
efficient manner in BSL-3 containment environments
where removal of paper is restricted. Laboratory managers
are able to view all audit findings and address them via
corrective action entries. In order to ensure 21 CFR, Part 11
compliance (http://www.access.gpo.gov/nara/cfr/waisidx_05/
21cfr11_05.html.), the QMS software utilizes an electronic
signature package allowing users to enter their username and
password to sign-off on training records, audit findings, and
equipmentmaintenance records, which provides an audit trail.
4. Personnel organization and training
Formal reporting structures must be in place, in compli-
ance with GCLP, to describe the relationships between the
EQAPOL Management and the EQAPOL Laboratory Teams.
Sollecito and Johnson describe communication as “necessary
not only within the team but also between the team and the
larger external environment, including other teams (Sollecito
and Johnson, 2012).” In addition, errors or lack of commu-
nication and coordination have been identified as the key
factors that lead to poor performance and detractors from
quality (Sollecito and Johnson, 2012). EQAPOL Management
created an organizational chart illustrating that relationship
and each EQAPOL Laboratory Team also developed a chart
describing the intra-laboratory management structure. Fig. 2
provides an example of an organizational chart that clearly
delineates the reporting structure within EQAPOL.
According to GCLP, personnel must successfully complete
required institutional, general safety and pathogen-specific
training before performing laboratory assays. EQAPOL utilized
the Duke University Occupational and Environmental Safety
Office's on-line training program for laboratory, biological
shipping, and other critical training (Chosewood et al., 2009;
OSHA, 1992). Additionally, any laboratory personnel performing
GCLP-compliant work must be able to document successful
completion of assay training and provide evidence that he/
she is competent by meeting pre-defined acceptance
criteria. The EQAPOL CQAU helped laboratories design and
implement SOPs for personnel training to assess initial and
ongoing competency of the operators. Competency of
operators must be assessed on a routine basis through annual
intra-laboratory testing.
EQAPOL
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Fig. 2. Example of organizational chart. This is an example of a GCLP-compliant organizational chart that represents the communication and reporting structure
within the EQAPOL Program.
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Equipment must be verified that it is “fit for purpose”
(Stiles et al., 2003) and must be maintained at high standards
for use in GCLP-related activities. Documentation must be
present to show that the equipment is properly installed,
operated, inspected, cleaned, maintained, tested, and cali-
brated to ensure that all results are of optimal quality (Ezzelle
et al., 2008; ISO/IEC, 2010). An essential component of the
initial laboratory assessments was to identify the pieces of
equipment that needed to meet these requirements based on
risk assessment. For those items that needed to be formally
validated, the CQAU assisted laboratory management in
developing validation plans according to ICH guidelines
(Guideline, 2010) and approving the validation before
execution and upon completion. Validation of equipment
helps assure that the item behaves accurately and consis-
tently over time. Each piece of equipment used in EQAPOL
receives a unique inventory number for quick reference in
the equipment database. All EQAPOL Laboratory Teams
manage their equipment in the QMS which captures the
unique inventory number, model number, serial number,
manufacturer, owner, equipment type, and location of the
equipment. For the seven EQAPOL Laboratory Teams, approx-
imately 250 pieces of equipment are currently catalogued and
maintained under GCLP conditions. Additionally, equipment
maintenance and calibration schedules (dependent upon the
manufacturer's recommendations) can be entered for each
equipment item. The QMS sends reminders to designatedpersonnel for upcoming and/or overdue service for equipment.
Data loggers are used by the EQAPOL Central Laboratory to
monitor the environment of all temperature-sensitive ship-
ments and provide assurance of the kit's quality to participating
sites.
6. Standard operating procedure development
An elaborate SOP structure was developed for all of the
EQAPOL Programs to help ensure that all procedures were
conducted in an identical manner to guarantee the quality
and integrity of generated data. GCLP guidelines require that
SOPs be written in a standard format similar to the one
recommended by the Clinical and Laboratory Standards
Institute (CLSI) (Ezzelle et al., 2008). An SOP framework
was already present in several EQAPOL Laboratory Teams,
facilitating the process of implementation. SOPs are reviewed
on a bi-annual basis with the EQAPOL CQAU managing
version control. With an SOP system in place, the majority of
SOPs that needed to be written were program-specific. For
example, each program within EQAPOL developed SOPs on:
• how to conduct the assay,
• training for the assay,
• proper instrument use and maintenance,
• reagent bridging, and
• data analysis.
In addition to program-specific SOPs, EQAPOL Manage-
ment developed SOPs that detailed how external proficiency
Table 1
Common audit findings and corrective actions.
Audit finding Potential corrective actions
Lack of reagent
bridging SOP
• Develop SOP for parallel testing to ensure
that all reagents used in kits perform
equivalently across rounds
Lack of/inconsistent
assay training
• Develop SOP for training new employees
and employees that have taken an extended
absence
• Develop training matrix stating required SOPs
No internal
competency testing
• Develop program to assess each operator's
ability to perform an assay
Lack of equipment
SOPs
• Develop common practices for using
equipment, calibration schedules and
preventative maintenance
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portal. While facilitating the control of SOPs, the QMS
notified users of the effective dates for new SOPs and sent
reminders when documents were due for review.
When conducting assays, EQAPOL laboratory operators are
required to complete assay-specific checklists to document
who performed each step. Assay checklists are associated to
version controlled SOPs and accessible through the QMS.
Checklists have been used in many industries as a way to
improve quality and safety (Sollecito and Johnson, 2012).
Recently, healthcare has also implemented checklists through-
outmany of its practices and an increasing amount of evidence
has begun to show their importance (Sollecito and Johnson,
2012).
7. Study Plans
In order to conduct a GCLP compliant study and proficiency
testing program, the Study Director needs to write a complete
Study Plan outlining the scope and conduct of the study.
Although EQAPOL is not fully adherent to ISO standards,
the Study Plan incorporates many of ISO's concepts. EQAPOL
Study Directors, Leadership, and the Statistical Group prepare
program-specific Study Plans for each round of testing under
the CQAU oversight. The EQAPOL Study Plans for proficiency
testing program include the following:
• a detailed list of the program's organizational and manage-
ment structure,
• introduction and background of the program,
• requirements for participation,
• number and type of program participants,
• proficiency panel contents,
• assay specifics,
• timeline for completion and upload of data,
• methods for data reporting,
• confidentiality, and
• methods for statistical analysis and grading.
EQAPOL Study Plans are approved and finalized by the
EQAPOL Study Directors, Leadership, the CQAU Director, and
the Statistician prior to the implementation of a particular EP
send-out. Study Plans provide evidence that the EQAPOL EP
was planned thoroughly and received Central Leadership
approval prior to the conduct of the study. The Study Plans
are not shared with the laboratories participating in the
proficiency testing programs, as they contain information that
could unblind their testing.
8. Audits
The EQAPOL CQAU performs internal and in-process audits
of each EQAPOL Laboratory Team (at least annually) as
required by GCLP guidelines to identify any potential gaps in
compliance and/or deviations from established protocols/
SOPs/Study Plans. Audits are performed by the EQAPOL CQAU
with the assistance of other QA personnel not involved in the
EQAPOL contract, to eliminate potential bias. Checklists are
used throughout all audits and reports are prepared with any
findings that need to be addressed. Laboratory personnel
then respond to the audit findings with appropriate
corrective actions to address the issues. The CQAU overseesthe proficiency test kit assembly, reagent preparation, and
shipment by the EQAPOL Central Laboratory, for at least one
send-out per year for each program. As these are often the
only proficiency testing materials that clinical trial immu-
nogenicity endpoint assay laboratories receive, it is crucial
that all aspects of the send-out are subject to CQAU
oversight. At the conclusion of the audits, the CQAU prepares
a report summarizing the kit preparation, send-out process
and congruence with what is described in the Study Plan.
Throughout the first series of audits, common findings
existed for many of the EQAPOL Laboratory Teams. These
non-conformances typically included a lack of a reagent
bridging SOP, assay-specific training SOP, internal compe-
tency testing program, and SOPs for all pieces of equipment
used during the conduct of the assay (Table 1).
9. Assay optimization, qualiﬁcation, and validation
In previously reported studies, performed by the CQAU, it
was demonstrated that it is easier to transfer an assay from
one laboratory to another when the assay had been
optimized and validated prior to the transfer (Ozaki et al.,
2012). This process led to high reproducibility of results
when inter-laboratory comparison was performed using a
proficiency testing program (Todd et al., 2012). Validating an
assay consists of analyzing the assay parameters recom-
mended by the ICH-Q2 (R1) guidelines (Guideline, 2010):
specificity, accuracy, precision, detection and quantitation
limits, linearity, range, and robustness. As an option exercised
by the NIAID contract, EQAPOL was charged with performing
a formal validation of the Neutralizing Antibody Assay for
HIV-1 in A3R5 cells. The process began with numerous
optimization experiments to help establish pre-set accep-
tance criteria for the formal validation experiments (Fig. 3)
(Sarzotti-Kelsoe et al., 2009). Applicable ICH parameters of
validation were selected and a validation plan, inclusive of a
statistical analysis plan, was written and authorized by the
CQAU. The assay validation was performed, data statistically
analyzed and a validation report was written and approved
by EQAPOL Leadership, Study Director, Statistician and CQAU,
and is reported in this issue (see Sarzotti-Kelsoe et al. in this
issue). This validated assay is being transferred to and
implemented by multiple laboratories and inter-laboratory
reproducibility will be determined by developing a proficiency
testing program for the A3R5 assay as a part of EQAPOL.
Optimization
Validation
Implementation
Development
Pre-Validation
Plan a logical transition from R&D to 
validation and develop an SOP for 
the assay.
Interpret ICH validation parameters 
for the assay.
Design experiments to address the 
specific parameters.
Determine acceptance criteria.
Write an official Validation Plan, 
have it authorized by QA.
Conduct the experiments and 
statistically analyze the results.
Write a Validation Report.
Implement the validated assay. 
Perform a “partial” 
Validation if the assay 
conditions change 
and/or assay is 
transferred to a new
laboratory. 
Fig. 3. Assay development to validation. This schematic diagram illustrates the steps necessary to validate an endpoint immunogenicity assay such as the A3R5
Neutralizing Antibody Assay.
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EQAPOL developed a Biorepository to manage all of the
reagents and samples used in the External Quality Assurance
(EQA) Programs, virus panel development, assay development,
and validation. All materials are recorded electronically in the
EQAPOL Application web-portal, which captures the reagent
name, lot number, expiration date, and storage location.
The EQAPOL Biorepository uses an electronic, wireless
temperature surveillance system for constant monitoring of all
freezers, refrigerators, and incubators. Repository staff members
receive alerts upon deviations from established temperature
ranges for all monitored equipment. With this temperature
monitoring software, the Biorepository manager and CQAU
auditors are able to view and determine when out-of-range
temperature excursions occurred, the operator who handled the
excursion, and the corrective action taken to address the
deviation. This information is stored permanently on the
EQAPOL server which is backed up nightly and the back-ups
are stored off-site. A Laboratory Data Management System
(LDMS) is utilized for the inventory of peripheral blood
mononuclear cells (PBMCs) that were processed from fresh
leukapheresis blood units and all source material and viruses
received/cultured as part of the EQAPOL Viral Diversity Program.
In accordancewithGCLP guidelines, all new lots or batches of
reagents and samples are parallel tested with previous lots to
document their compatibility in the assay prior to being placed
into use. Each EOL defined in SOPs the critical reagents required
to be parallel tested as well as pass and fail criteria for their
eligibility to be placed in proficiency testing kits. Examples of
such reagents include PBMCs, Fetal Bovine Serum (FBS), and
Streptavidin. Reagents that did not pass parallel testingwere not
permitted for use in the EQA proficiency test kits.
11. EQAPOL ordering, shipping and data reporting: web-
based portal
As another aspect of the EQAPOL system, a user-friendly
and comprehensive web-based portal was developed tosecure all of the electronic data generated from the program.
The web-based portal was developed specifically for the
needs of EQAPOL by SciMed Solutions and operates in
compliance with the Federal Information Security Manage-
ment Act of 2002 (FISMA, 2006). Within the system,
laboratories and individual users are given roles that are
used to define which aspects of the system they can view.
This is of particular importance for the EQA programs where
sites should only see their own data.
The EQAPOL web portal is used to document all aspects of
each EQA program from send-out of material information to
data upload to EQA report retrieval. It maintains reagent and
specimen inventory and location, as well as certificates of
analysis for reagents. For each EQA send-out, the system
records all samples/reagents sent to each site, shipment
manifests, tracking information and shipment sent/receipt
dates. For each EQA sendout, sites can download assay
protocols and data reporting templates on the web-based
system. Once a site completes an assay, the data reporting
template is completed and returned using the web-based
system. Sites also complete a post-assay questionnaire using
the portal. As data are received from each site, the templates
undergo data verification to ensure that the data are in the
proper format prior to importing them into the EQAPOL
database. Specific data verification instructions have been
developed for each EQA program. The EQAPOL statisticians
access all EQA data directly from this database ensuring data
integrity throughout the system.
Once the statisticians complete all data analysis, site-specific
reports are generated and uploaded to the web-based system
with each site having access to their site report. Sites receive
both a score out of 100 and a performance rating for each EP,
with points awarded for different performance criteria (i.e.,
precision, accuracy, protocol adherence). These scores and
performance ratings are entered into the web-based system
to allow performance tracking over time. Finally, the
web-based system can capture comments and files used as
part of the remediation process. This comprehensive system
allows for complete traceability of the EQA process.
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viral samples that are prepared by the EQAPOL Viral Diversity
Core. Additionally, the portal captures virus culture and
characterization data, and provides a means for approved
laboratories to view virus inventory and order products. The
system maintains an electronic inventory of all specimens and
reagents for EQAPOL, and all applicable compliance informa-
tion (Institutional Review Board, Material Transfer Agreement
and Safety Compliance Forms) to ensure that sites only receive
material which they are authorized to receive. These orders are
then processed by EQAPOL Program Management and sent
through an approval process.
12. Reporting to EQAPOL Leadership
A key aspect to maintaining GCLP-compliance within the
EQAPOL Program is to keep Leadership abreast of key quality
issues on a regular basis. The EQAPOL CQAU meets with the
EQAPOL Steering Committee on a bi-weekly basis with
updates on audits, SOP development, proficiency testing kit
preparation and shipment status, and other key quality
matters. The Steering Committee is comprised of the Program
Director and Co-Director, Study Directors, IT Personnel,
Finance, Regulatory Affairs Compliance, Statisticians, CQAU
and other critical program managers. In addition, the CQAU
presents annual progress updates to the EQAPOL External
Scientific Advisory Board and receives feedback from the
Board.
13. Archives
The EQAPOL CQAU provides archival functions for all
study and proficiency testing materials. The materials are
required to be kept in case a study needs to be investigated.
Obsolete SOPs, study plans, raw data, and quality control
documents are given to the EQAPOL CQAU and are stored in a
space that has restricted access and is separated from the
laboratory environment. Archived material is maintained
indefinitely or until the Sponsor has requested destruction of
the documents. In addition to on-site archiving, the CQAU has
contracted with a third party sub-contractor to store
documents off-site for extended periods of time.
14. Discussion
Implementation of GCLP into the EQAPOL Laboratory Teams
began with an initial laboratory assessment, followed by GCLP
training of laboratory staff, implementation of a QMS, equip-
ment qualification, SOP document control, and audits by the
CQAU. Converting EQAPOL into a GCLP-compliant operation
has a number of added benefits that include increased
credibility for the program and improved accuracy, integrity,
and traceability of generated data. Having a CQAU in charge of
monitoring the EQAPOL project has allowed for more stringent
quality control measures of all processes within the program.
Implementing GCLP guidelines designed for clinical trial
testing into a setting for proficiency testing was ultimately a
challenge for the EQAPOL CQAU. Converting all of the
EQAPOL Laboratory Teams into GCLP-compliant laboratories
required approximately two years and multiple hurdles were
encountered along the way. One of the primary challengesfor the EQAPOL Program was unifying all of the programs
under one system of SOPs and document control. Since EOLs
were members of different departments within Duke, not all
of them followed the same system of SOPs. To address this
dilemma, the QAU utilized an electronic QMS which ulti-
mately incorporated multiple sets of pre-existing SOPs.
Additionally, the CQAU did eliminate SOP redundancies by
creating an overarching system of SOPs that were to govern
common processes across all programs.
SOP development for new GCLP assays was also a
considerable hurdle because some of the laboratories lacked
experience in the creation and usage of SOPs. Commitment
from laboratories is typically weak at the beginning of GCLP
conversion and leads to many delays in SOP finalization. The
quicker a laboratory “bought-in” to the concept and impor-
tance of GCLP, the smoother the overall transition went.
Throughout this two-year process, it became evident that
those laboratories that had already implemented some of the
key GCLP components into their operations were better
prepared to become GCLP-complaint.
The up-front cost of operating a laboratory under GCLP is
often seen as a hurdle, yet mistakes are often more costly then
preventative measures (Crosby, 1979). Utilizing the EQAPOL
contract, it has been possible to estimate that full implementa-
tion of GCLP into a laboratory increases operating costs by close
to 20% (G. Sempowski, personal communication). This figure is
based on financial estimates from laboratories with pre-existing
quality controlmeasures such as service contracts for equipment
maintenance and calibration, standardized protocols, and re-
agent inventory systems. Pending funding approval, EQAPOL is
considering ISO/IEC 17043 accreditation for the proficiency
testing program. Although ISO/IEC accreditation is not a
contractual requirement, it would add consistency and quality
to all aspects of the program. Accreditation is a mechanism that
would reassure external participants that quality and safety
standards are demonstrated throughout the program (Sollecito
and Johnson, 2012).
GCLP implementation and compliance in the EQAPOL
laboratories have provided assurance that all processes are
planned, performed, monitored, recorded, and reported in a
reliable and consistent manner. Program participants can be
assured that the kits are assembled with the utmost quality
and detail and that all handling of data and statistical analysis
had been thoroughly planned and executed. Ultimately, GCLP
programs, such as EQAPOL, strengthen laboratory's ability to
perform critical assays and provide quality assessments of
potential vaccines in the future. Quality improvement within
EQAPOL Laboratory Teams is an ongoing process and changes
will continue to be made with future funding so that all
aspects of the program can operate at the highest level of
compliance possible.
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